Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
NBY - NovaBay Pharmaceuticals - AMEX
Volgen
Ik verwacht de komende weken een uitbraak. 3 catalysts in Q4 wat de prijs van dit aandeel omhoog zou moeten brengen. Zit erin op 1.45 Daily Chart: stockcharts.com/c-sc/sc?s=NBY&p=D... Weekly Chart: stockcharts.com/c-sc/sc?s=NBY&p=W... News: finance.yahoo.com/q/h?s=nby+Headlines Near-Term: For Urology and their Phase 2 trial they are expecting dose enrollment to have last patient at end of July. There will be a database lock with data at end of Q3 or beginning Q4. For Dermatology (300pt study in impetigo) study they will close study at the end of July with database lock then results in Q4. They also have their Ophthalmology study (BayNovation study) that is due to report at the end of Q4 as well. Market cap is only 52m as the company has 37m shares o/s and 30m in the float. The company has 14m in cash & no-debt. "As of the Record Date of April 24th, 37,318,981 shares of our common stock were outstanding, and no shares of our preferred stock were outstanding." NovaBay: Upcoming Auriclosene Data Could Be A Catalyst - Seeking Alpha bit.ly/1637MN0 June 11th: NovaBay Pharma provides Mid-Year Clinical Update; Clinical Results From Three Auriclosene Phase 2 Trials... bit.ly/11cTioN Co announced several business and clinical updates for the remainder of 2013. Dr. Ron Najafi, Chairman and CEO of NovaBay Pharmaceuticals, explained, "This is an important year for NovaBay. Each of our three auriclosene phase 2 clinical studies -- in urology, dermatology, and ophthalmology -- is expected to report data in the second half of 2013. We are excited that the differentiated products we are developing will positively impact patients' lives once approved." Read more: www.briefing.com/Investor/PopupPages/... Second look at Novabay: Working on effective treatment for viral conjunctivitis: bit.ly/14pJkqB Novabay: A novel Agent against a common problem. bit.ly/12MHxdF Dec 6th , 2012 NBY offering. 5.9M shares at $1.25/share. bit.ly/TEFM9H June 11th Shareholder Presentation Mtng Slides: bit.ly/14H6xnG Urology Study to Evaluate NVC-422 for Urinary Catheter Blockage and Encrustation www.clinicaltrials.gov/ct2/show/NCT01... Dermatology www.clinicaltrials.gov/ct2/show/NCT01... Ophthalmology: www.baynovation.org or www.clinicaltrials.gov/ct2/show/NCT01...
Heeft zich de afgelopen 6 weken min of meer nauwelijks bewogen maar vandaag gaat NBY dan toch up op een mooi volume. NovaBay Pharmaceuticals Announces Positive Results from Phase 2 Clinical Study of Auriclosene to Reduce Urinary Catheter Bloc... Primary Endpoints Achieved Showing Statistically Significant and Clinically Meaningful Benefits for Patients with Long-Term Indwelling Catheters Results Pave the Way for Phase 3 Pivotal Studies
Gisteren wederom een mooie dag voor NBY. Gesloten op 1,80. Als je kijkt naar de weekly chart zie je dat NBY voor het laatst 1.80 aantikte in mei 2011. Al met al is dit dus een mooie uitbraak die gepaard gaat met een volume dat de afgelopen jaren nog niet zo hoog is geweest. Goed teken! Op de weekly chart is nog ruimte voor stijging, de daily begint wat overbought te raken.
1.90 nu. Sta op het punt om uit te stappen, even aankijken nog
Mooi slot op 1.94 Heb ze nog steeds
Doniss schreef op 23 september 2013 20:01 :
Stoploss gezet op 1.96
En de stoploss is afgegaan. Entry was 1.45 Ik ben tevreden met 35% winst.
EMERYVILLE, Calif. (May 14, 2020) – NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that CEO Justin Hall has issued the following letter to stockholders:novabay.com/pressreleases/novabay-pha... Novabay Pharmaceuticals Inc gaat waarschijnlijk veel hoger open vanmiddag dan vorig slot 0,94 Staat nu een bied en laat van 1,15 .... 1,18 Wie zit hier nog in?
. EMERYVILLE, Calif. (May 14, 2020) – NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that CEO Justin Hall has issued the following letter to stockholders: To My Fellow Stockholders: As pandemic-related shelter-in-place restrictions are beginning to lift in certain geographies and Americans are preparing to return to school, work and social activities, NovaBay has focused on offering our fellow Americans products they need to help them stay safe. NovaBay has business contacts around the globe, and we worked tirelessly with them to secure quality COVID-19 personal-protection and diagnostic products, while at the same time continuing to advance our previously announced cost-efficient sales and marketing strategy for Avenova®. I’m gratified to report this parallel strategy is working very well, with combined product sales in the month of April surpassing our total revenue for the entire first quarter. Just as Avenova is considered the highest quality product in its market segment, we are also confident in the quality of the new products we are securing for U.S. distribution in response to the COVID-19 pandemic. Our confidence is based on the reputation of our suppliers as well as the results from third-party lab testing. We began selling KN95 masks through our website Avenova.com less than two months ago, and we are already nearing the milestone of one million units sold. These KN95 masks are effective in filtering out at least 95 percent of airborne particles, including microorganisms, dust, pollen and air pollution, making them ideal for personal protection in public places. We are highly confident in their design as they are CE certified and meet the KN95-level requirements. In order to distinguish them from the many inferior quality masks currently in the marketplace, our partner mask manufacturer has submitted the KN95 masks for emergency use authorization (“EUA”) from the U.S. FDA to further validate their quality. Due to the backlog of new COVID-19 related products submitted, the FDA has not given us a timeframe for review. While many Americans continue to have difficulty acquiring masks, our masks are in stock in the U.S. and ready for immediate shipping, with customers typically receiving them within a day or two of ordering. Most of our current volume is attributable to bulk orders from large institutions. We expect that pattern will continue in the near term and that our KN95 mask sales through Avenova.com will remain fairly steady with April levels. We are also offering a special promotion combo pack of 30 masks and two bottles of Avenova for $199. Avenova, with its antimicrobial properties and applied as a facial spray, is a perfect complement to the mask. I’m pleased to report that some companies are placing bulk orders for this combo pack and shipping them directly to their employees’ homes as a gesture of goodwill. Less than a month ago, we announced an exclusive U.S. distribution agreement for a highly sensitive rapid, point-of-care, finger prick COVID-19 antibody test. Public health experts and leaders across the country are citing a critical need for mass testing and tracing procedures for those who have been infected with COVID-19 as a condition for safely reopening our economy. As work and social activities resume, we expect that testing will become an even greater priority to determine who is actively infected and who may have antibodies against the pathogen. Importantly, we are confident in the reliability of our product versus some questionable tests that have been introduced to the market. We believe the accuracy of our test is comparable to those already receiving EUA from the FDA. We filed for EUA approval on April 17 and remain in regular contact with the FDA reviewer assigned to evaluate our test. Regulatory reviews of COVID-19 antibody tests have been slow as the FDA is tirelessly working through a backlog of submissions. To be clear, we will not be selling this point-of-care test until such time as EUA from the FDA has been received. Once granted, we will begin marketing the test through our sales team to healthcare professionals across the country, who then will administer the test. The test uses a drop of whole blood for the detection of COVID-19 antibodies, with results available in approximately 10 minutes. Our test detects for the presence of both IgM and IgG. IgM is usually the first antibody generated by the body in response to the coronavirus. Later, the IgG antibody is generated and replaces IgM as the predominant antibody in response to the infection. While in some ways our test is similar to others on the market, it is differentiated by its use of a slightly larger blood sample to improve accuracy and shortened testing time of 10 minutes versus 20 minutes with others. Additionally, our test is self-contained without the need for additional materials or ancillary reagents, which competing tests require. While we are confident in the quality of our test, because of the fast-changing regulatory landscape, we cannot give guidance on the timeline for FDA review or whether we will receive clearance for commercial marketing and sale. Our sales team is in place and eager for this new opportunity.
Deel 2 During this time of shelter-in-place, our team is also focusing on promoting Avenova, both online and to doctors in historically high-performing territories. We introduced Avenova Direct as a prescription-strength consumer product last June, and online sales during the 2020 first quarter accounted for more than half of all Avenova revenue for the very first time. We previously announced the introduction of refreshed consumer branding for Avenova with new packaging and reinvigorating messaging that emphasizes quality-of-life themes. While e-commerce sales are becoming a growing percentage of the total, we are pursuing a strategy to cost-effectively expand our customer base. We are pleased by the reception to our refreshed branding, and we’re open to the opportunity to increase sales through affiliate relationships to help reach the 41 million Americans who suffer from blepharitis and related eye conditions. NovaBay’s proprietary pure hypochlorous acid (HOCl) is a form of an antibacterial/antimicrobial agent naturally produced by the human body in response to pathogens. HOCl has also been endorsed by the Centers for Disease Control and Prevention (CDC) as a disinfectant useful against SARS-CoV-2. We are conducting third-party laboratory tests to verify the efficacy of our specific formulation against the SARS-CoV-2 pathogen. The popularity of Avenova could significantly increase as Americans seek alternative disinfectant solutions that are proven to be safe and well-tolerated on human skin, including the face and sensitive area around the eyes. Americans have become educated to the CDC warning against touching one’s face as this significantly increases the risk of potential infection. Avenova is manufactured in the U.S. and the supply chain for its components is currently robust. We are increasing our advertising to broaden our customer base of regular long-term users. Also in keeping with our strategy, we are targeting ophthalmic and skin care product line extensions that will leverage our salesforce and our sales channels under economics that make sense for NovaBay. We are pursuing a range of options including product licensing and acquisitions. While we look forward to a return to more normalized business operation, NovaBay continues to work hard under remote conditions. I’d like to thank my colleagues for our shared dedication to success, and also thank our stockholders for your confidence in the NovaBay team as we build stockholder value. Sincerely, Justin M. Hall, Esq. Chief Executive Officer and General Counsel PS. Please note we are holding a virtual Annual Meeting of Stockholders on May 26, 2020 beginning at 5:00 p.m. Pacific Time. Instructions for joining the meeting are in the proxy materials sent to stockholders as of our Record Date. We appreciate your support for the initiatives our Board has endorsed.
Novabay gaat de laatste dagen goed omhoog. Nieuws?
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
865,36
+0,00%
EUR/USD
1,0647
-0,22%
FTSE 100
7.877,05
+0,37%
Germany40^
17.754,80
-0,09%
Gold spot
2.381,57
+0,87%
NY-Nasdaq Composite
15.683,37
-1,15%
Stijgers
Dalers